<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01745107</url>
  </required_header>
  <id_info>
    <org_study_id>Z121107001012004</org_study_id>
    <secondary_id>Z121107001012004</secondary_id>
    <nct_id>NCT01745107</nct_id>
  </id_info>
  <brief_title>Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma;</brief_title>
  <acronym>IMRT</acronym>
  <official_title>Phase Ⅲ Study of Prophylactic Postoperative Intensity Modulated Radiation Therapy in Stage T2-3N0M0 Disease of Thoracic Esophageal Squamous Cell Carcinoma;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sichuan Cancer Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of preventive intensity modulated
      radiation therapy after surgery in stage T2-3N0M0 disease of thoracic esophageal squamous
      cell carcinoma(UICC 7th edition) and to identify the subgroup benefiting from the treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although preoperative chemoradiation therapy followed by surgery is the most common approach
      for patients with resectable esophageal cancer, the considerable number of esophageal cancer
      patients received operation as the first treatment modality. Accordingly, postoperative
      treatments have been playing an important role because of the poor survival rates of the
      patients who have been treated with resection alone. The existing data shows that the 5-yeal
      survival rate of stage T2-3N0M0(UICC 7th edition) of thoracic esophageal squamous cell
      carcinoma(TESCC) after surgery is about 50% ,and locoregional lymph nodes metastases is
      responsible for the main cause of failure while distal metastases account for relatively less
      ratio. Therefore, the subclinical residual tumor is affirmative even if the early disease has
      been undergone curable excision and local adjuvant treatment may be essential. While we have
      proved the value of prophylactic radiation therapy after radical esophagectomy for esophageal
      carcinoma with positive lymph node metastases and stage Ⅲ disease, there is still lack of
      clear evidence for prophylactic radiation therapy in stage T2-3N0M0 disease now. The
      comparison of conventional 2-dimensional radiotherapy after operation versus surgery alone
      does not show statistically significant difference for stage T2-3N0M0 disease in our previous
      report. In the precise radiotherapy setting, more and more evidences of non-randomised
      control study indicate the trend or preliminary results of dosimetric advantages of IMRT
      translating into substantive benefits in both survival and locoregional control compared with
      3- dimensional conformal and 2-dimensional conventional radiotherapy for the treatment of
      esophageal carcinoma, but it remains to be confirmed in the randomized control study that
      whether the IMRT is effective to improve the clinical outcomes of stage T2-3N0M0 patients of
      TESCC. In view of this, we designed the randomized controlled trial to determine the clinical
      efficacy and toxicity of prophylactic IMRT after surgery in stage T2-3N0M0 disease of TESCC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival time</measure>
    <time_frame>up to 3 years</time_frame>
    <description>including survival time from randomization to locoregional recurrence and to distal metastasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival time</measure>
    <time_frame>up to 5 years</time_frame>
    <description>survival time from randomization to death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Esophageal Neoplasm</condition>
  <condition>Esophageal Cancer TNM Staging Primary Tumor (T) T2</condition>
  <condition>Esophageal Cancer TNM Staging Primary Tumor (T) T3</condition>
  <condition>Esophageal Cancer TNM Staging Regional Lymph Nodes (N) N0</condition>
  <condition>Esophageal Cancer TNM Staging Distal Metastasis (M) M0</condition>
  <arm_group>
    <arm_group_label>surgery alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No prophylactic postoperative radiation therapy,that is surgery alone is developed in this arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>surgery plus radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prophylactic postoperative radiation therapy is developed in this arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Prophylactic postoperative radiation therapy</intervention_name>
    <description>Prescription dose of 95%planning target volume(PTV) 50.4Gy/1.8Gy/28fractions for supraclavicular region and 95%PTV 56Gy/2Gy/28fractions for mediastinum which is delivered in 2 months after surgery.</description>
    <arm_group_label>surgery plus radiation</arm_group_label>
    <other_name>Preventive postoperative radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage T2-3N0M0 disease of TESCC patients confirmed by pathology studies who received
             R0 operations in Cancer Institute &amp; Hospital，CAMS；

          -  KPS≥70 before radiotherapy;

          -  Did not receive neoadjuvant or adjuvant treatment;

          -  No clear recurrent or metastatic lesions before radiotherapy;

          -  Intensity modulated radiation therapy(IMRT) is accepted;

          -  Regular follow-up.

        Exclusion Criteria:

          -  Exploratory thoracotomy or palliative surgery;

          -  No clear recurrent or metastatic sites;

          -  Recurrence or metastasis is not certain;

          -  death of no definite cause.

          -  Irregular follow-up;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zefen Xiao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Department of Radiation Oncology ,Cancer Institute &amp; Hospital，Chinese Academy of Medical Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zenfen Xiao, MD</last_name>
    <phone>8610-87787643</phone>
    <email>xiaozefen@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Deng, MD</last_name>
    <phone>86-18813019080</phone>
    <email>sherrydw@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer institute &amp; Hospital，Chinese Academy of Medical Science</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zefen Xiao, MD</last_name>
      <phone>8610-87787643</phone>
      <email>Xiaozefen@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Wei Deng, MD</last_name>
      <phone>86-18813019080</phone>
      <email>sherrydw@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.cicams.ac.cn</url>
    <description>It is a national center for cancer research and treatment. It is one of the clinical trial bases approved by the Food and Drug Administration of State (SFDA)</description>
  </link>
  <reference>
    <citation>Xiao ZF, Yang ZY, Liang J, Miao YJ, Wang M, Yin WB, Gu XZ, Zhang DC, Zhang RG, Wang LJ. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg. 2003 Feb;75(2):331-6.</citation>
    <PMID>12607634</PMID>
  </reference>
  <reference>
    <citation>Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1078-85. doi: 10.1016/j.ijrobp.2012.02.015. Epub 2012 Aug 3.</citation>
    <PMID>22867894</PMID>
  </reference>
  <reference>
    <citation>Chen J, Zhu J, Pan J, Zhu K, Zheng X, Chen M, Wang J, Liao Z. Postoperative radiotherapy improved survival of poor prognostic squamous cell carcinoma esophagus. Ann Thorac Surg. 2010 Aug;90(2):435-42. doi: 10.1016/j.athoracsur.2010.04.002.</citation>
    <PMID>20667325</PMID>
  </reference>
  <reference>
    <citation>Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer. 2003 Apr 1;97(7):1616-23.</citation>
    <PMID>12655517</PMID>
  </reference>
  <reference>
    <citation>Nishimaki T, Suzuki T, Suzuki S, Kuwabara S, Hatakeyama K. Outcomes of extended radical esophagectomy for thoracic esophageal cancer. J Am Coll Surg. 1998 Mar;186(3):306-12.</citation>
    <PMID>9510261</PMID>
  </reference>
  <reference>
    <citation>Reeh M, Nentwich MF, von Loga K, Schade J, Uzunoglu FG, Koenig AM, Bockhorn M, Rosch T, Izbicki JR, Bogoevski D. An attempt at validation of the Seventh edition of the classification by the International Union Against Cancer for esophageal carcinoma. Ann Thorac Surg. 2012 Mar;93(3):890-6. doi: 10.1016/j.athoracsur.2011.11.035. Epub 2012 Jan 29.</citation>
    <PMID>22289905</PMID>
  </reference>
  <reference>
    <citation>Isono K, Sato H, Nakayama K. Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology. 1991;48(5):411-20.</citation>
    <PMID>1745490</PMID>
  </reference>
  <reference>
    <citation>Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg. 1994 Sep;220(3):364-72; discussion 372-3.</citation>
    <PMID>8092902</PMID>
  </reference>
  <reference>
    <citation>Chen J, Sang M, Chen Y. [Recurrence pattern and prognosis of esophageal cancer following tumor resection]. Zhonghua Zhong Liu Za Zhi. 1998 Jul;20(4):293-5. Chinese.</citation>
    <PMID>10920988</PMID>
  </reference>
  <reference>
    <citation>Visbal AL, Allen MS, Miller DL, Deschamps C, Trastek VF, Pairolero PC. Ivor Lewis esophagogastrectomy for esophageal cancer. Ann Thorac Surg. 2001 Jun;71(6):1803-8.</citation>
    <PMID>11426751</PMID>
  </reference>
  <reference>
    <citation>Ténière P, Hay JM, Fingerhut A, Fagniez PL. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet. 1991 Aug;173(2):123-30.</citation>
    <PMID>1925862</PMID>
  </reference>
  <reference>
    <citation>Fok M, Sham JS, Choy D, Cheng SW, Wong J. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery. 1993 Feb;113(2):138-47.</citation>
    <PMID>8430362</PMID>
  </reference>
  <reference>
    <citation>Zieren HU, Müller JM, Jacobi CA, Pichlmaier H, Müller RP, Staar S. Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg. 1995 May-Jun;19(3):444-9.</citation>
    <PMID>7639004</PMID>
  </reference>
  <reference>
    <citation>Chen G, Wang Z, Liu XY, Liu FY. Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esophagectomy. World J Surg. 2007 May;31(5):1107-14.</citation>
    <PMID>17426905</PMID>
  </reference>
  <reference>
    <citation>Xiao ZF, Yang ZY, Miao YJ, Wang LH, Yin WB, Gu XZ, Zhang DC, Sun KL, Chen GY, He J. Influence of number of metastatic lymph nodes on survival of curative resected thoracic esophageal cancer patients and value of radiotherapy: report of 549 cases. Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):82-90.</citation>
    <PMID>15850906</PMID>
  </reference>
  <reference>
    <citation>Chen J, Pan J, Zheng X, Zhu K, Li J, Chen M, Wang J, Liao Z. Number and location of positive nodes, postoperative radiotherapy, and survival after esophagectomy with three-field lymph node dissection for thoracic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):475-82. doi: 10.1016/j.ijrobp.2010.08.037. Epub 2010 Oct 8.</citation>
    <PMID>20934269</PMID>
  </reference>
  <reference>
    <citation>Bédard EL, Inculet RI, Malthaner RA, Brecevic E, Vincent M, Dar R. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer. 2001 Jun 15;91(12):2423-30.</citation>
    <PMID>11413534</PMID>
  </reference>
  <reference>
    <citation>Qiao XY, Wang W, Zhou ZG, Gao XS, Chang JY. Comparison of efficacy of regional and extensive clinical target volumes in postoperative radiotherapy for esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):396-402. Epub 2007 Sep 12.</citation>
    <PMID>17855004</PMID>
  </reference>
  <reference>
    <citation>Zhang Wencheng,Wang Qifeng,Xiao Zefen,et al.A efficacy analysis of intensity-modulated radiotherapy or three-dimensional conformal radiotherapy for resected thoracic esophageal squamous cell carcinoma.Chinese Journal of Radiation Oncology.2012,21(2):136-139.DOI:10.3760/cma.j.issn.1004-4221.2012.02.012.</citation>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2012</study_first_submitted>
  <study_first_submitted_qc>December 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2012</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zefen Xiao</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>T2-3N0M0 disease of esophageal neoplasm</keyword>
  <keyword>postoperative radiotherapy</keyword>
  <keyword>intensity modulated radiation therapy</keyword>
  <keyword>survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

